Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Sana Biotechnology Inc has a consensus price target of $9.25 based on the ratings of 9 analysts. The high is $15 issued by Citigroup on August 9, 2024. The low is $5 issued by JMP Securities on June 24, 2025. The 3 most-recent analyst ratings were released by Morgan Stanley, JMP Securities, and HC Wainwright & Co. on July 3, 2025, June 24, 2025, and April 24, 2025, respectively. With an average price target of $9.33 between Morgan Stanley, JMP Securities, and HC Wainwright & Co., there's an implied 130.74% upside for Sana Biotechnology Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
07/03/2025 | Buy Now | 196.66% | Morgan Stanley | Maxwell Skor22% | → $12 | Assumes | → Overweight | Get Alert |
06/24/2025 | Buy Now | 23.61% | JMP Securities | Reni Benjamin48% | $5 → $5 | Reiterates | Market Outperform → Market Outperform | Get Alert |
04/24/2025 | Buy Now | 171.94% | HC Wainwright & Co. | Emily Bodnar39% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
03/18/2025 | Buy Now | 23.61% | Citizens Capital Markets | Reni Benjamin48% | → $5 | Upgrade | Market Perform → Market Outperform | Get Alert |
03/18/2025 | Buy Now | 171.94% | HC Wainwright & Co. | Emily Bodnar39% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
03/14/2025 | Buy Now | 73.05% | Jefferies | Roger Song39% | → $7 | Initiates | → Buy | Get Alert |
01/08/2025 | Buy Now | 171.94% | HC Wainwright & Co. | Emily Bodnar39% | $8 → $11 | Maintains | Buy | Get Alert |
01/08/2025 | Buy Now | — | TD Cowen | Marc Frahm23% | — | Upgrade | Hold → Buy | Get Alert |
11/27/2024 | Buy Now | 97.78% | HC Wainwright & Co. | Emily Bodnar39% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
11/11/2024 | Buy Now | 97.78% | HC Wainwright & Co. | Emily Bodnar39% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
11/05/2024 | Buy Now | — | JMP Securities | Reni Benjamin48% | — | Downgrade | Market Outperform → Market Perform | Get Alert |
11/05/2024 | Buy Now | 97.78% | HC Wainwright & Co. | Emily Bodnar39% | $11 → $8 | Maintains | Buy | Get Alert |
08/09/2024 | Buy Now | 270.83% | Citigroup | Samantha Semenkow31% | $8 → $15 | Maintains | Buy | Get Alert |
08/09/2024 | Buy Now | 171.94% | HC Wainwright & Co. | Emily Bodnar39% | $12 → $11 | Maintains | Buy | Get Alert |
05/09/2024 | Buy Now | 196.66% | HC Wainwright & Co. | Emily Bodnar39% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
03/01/2024 | Buy Now | 196.66% | HC Wainwright & Co. | Emily Bodnar39% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
03/01/2024 | Buy Now | 270.83% | JMP Securities | Reni Benjamin48% | $8 → $15 | Maintains | Market Outperform | Get Alert |
01/16/2024 | Buy Now | 196.66% | HC Wainwright & Co. | Emily Bodnar39% | → $12 | Upgrade | Neutral → Buy | Get Alert |
10/12/2023 | Buy Now | 97.78% | JMP Securities | Reni Benjamin48% | $9 → $8 | Maintains | Market Outperform | Get Alert |
09/25/2023 | Buy Now | 122.5% | JMP Securities | Reni Benjamin48% | → $9 | Initiates | → Market Outperform | Get Alert |
09/05/2023 | Buy Now | 97.78% | Citigroup | Samantha Semenkow31% | → $8 | Initiates | → Buy | Get Alert |
08/14/2023 | Buy Now | — | TD Cowen | Marc Frahm23% | — | Initiates | → Market Perform | Get Alert |
05/02/2023 | Buy Now | — | HC Wainwright & Co. | Emily Bodnar39% | — | Initiates | → Neutral | Get Alert |
01/24/2023 | Buy Now | 221.38% | Morgan Stanley | Matthew Harrison60% | $15 → $13 | Maintains | Overweight | Get Alert |
11/03/2022 | Buy Now | 48.33% | Goldman Sachs | Salveen Richter53% | $7 → $6 | Maintains | Neutral | Get Alert |
The latest price target for Sana Biotechnology (NASDAQ:SANA) was reported by Morgan Stanley on July 3, 2025. The analyst firm set a price target for $12.00 expecting SANA to rise to within 12 months (a possible 196.66% upside). 14 analyst firms have reported ratings in the last year.
The latest analyst rating for Sana Biotechnology (NASDAQ:SANA) was provided by Morgan Stanley, and Sana Biotechnology their overweight rating.
The last upgrade for Sana Biotechnology Inc happened on March 18, 2025 when Citizens Capital Markets raised their price target to $5. Citizens Capital Markets previously had a market perform for Sana Biotechnology Inc.
The last downgrade for Sana Biotechnology Inc happened on November 5, 2024 when JMP Securities changed their price target from N/A to N/A for Sana Biotechnology Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sana Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sana Biotechnology was filed on July 3, 2025 so you should expect the next rating to be made available sometime around July 3, 2026.
While ratings are subjective and will change, the latest Sana Biotechnology (SANA) rating was a with a price target of $0.00 to $12.00. The current price Sana Biotechnology (SANA) is trading at is $4.05, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.